RxSight Dirección
Dirección controles de criterios 3/4
El CEO de RxSight es Ron Kurtz , nombrado en Jan 2016, tiene una permanencia de 8.92 años. compensación anual total es $3.08M, compuesta por 20.6% salario y 79.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.05% de las acciones de la empresa, por valor de $37.96M. La antigüedad media del equipo directivo y de la junta directiva es de 4.2 años y 3.3 años, respectivamente.
Información clave
Ron Kurtz
Chief Executive Officer (CEO)
US$3.1m
Compensación total
| Porcentaje del salario del CEO | 20.6% |
| Permanencia del CEO | 8.9yrs |
| Participación del CEO | 2.1% |
| Permanencia media de la dirección | 4.2yrs |
| Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Nov 29We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$31m |
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$3m | US$633k | -US$49m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$1m | US$563k | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$67m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$5m | US$445k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | US$17m |
| Dec 31 2020 | US$741k | US$310k | US$3m |
Compensación vs. Mercado: La compensación total de Ron($USD3.08M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD5.36M).
Compensación vs. Ingresos: La compensación de Ron ha aumentado mientras la empresa no es rentable.
CEO
Ron Kurtz (61 yo)
8.9yrs
Permanencia
US$3,081,597
Compensación
Dr. Ronald M. Kurtz, also known as Ron, M.D., serves as President and Chief Executive Officer at RxSight, Inc. (formerly Calhoun Vision) since January 2016 and also serves as its Director since February 20...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 8.9yrs | US$3.08m | 2.05% $ 38.0m | |
| Co-President & Chief Commercial Officer | 9.5yrs | US$1.65m | 0.76% $ 14.1m | |
| Co-President & Chief Financial Officer | 7.8yrs | US$1.89m | 0.076% $ 1.4m | |
| Co-President & Chief Operating Officer | 5.5yrs | US$1.89m | 0.11% $ 2.0m | |
| Vice President of Accounting & Finance | no data | sin datos | sin datos | |
| Chief Technology Officer | no data | sin datos | sin datos | |
| Vice President of Investor Relations | 1.1yrs | sin datos | sin datos | |
| Senior VP of Sales of North America | less than a year | sin datos | sin datos | |
| Senior VP of Marketing & Professional Relations | 2.9yrs | sin datos | sin datos | |
| Vice President of Human Resources | 9.3yrs | sin datos | sin datos | |
| Executive VP of Manufacturing & Commercial Operations | 2.9yrs | sin datos | sin datos | |
| Executive VP of Clinical & Regulatory Affairs | 2.8yrs | sin datos | sin datos |
4.2yrs
Permanencia media
62yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RXST se considera experimentado (4.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 8.8yrs | US$3.08m | 2.05% $ 38.0m | |
| Director | 8.1yrs | US$204.98k | 0.11% $ 2.1m | |
| Independent Director | 3.3yrs | US$209.98k | 0.062% $ 1.2m | |
| Independent Director | 9.5yrs | US$209.98k | 0.090% $ 1.7m | |
| Independent Chairman of the Board | 9.9yrs | US$257.48k | 1.33% $ 24.6m | |
| Independent Director | 2.9yrs | US$204.98k | 0.057% $ 1.0m | |
| Independent Director | 3.3yrs | US$214.98k | 0.062% $ 1.2m | |
| Independent Director | 3.3yrs | US$212.48k | 0.062% $ 1.2m | |
| Independent Director | 3yrs | US$199.98k | 0.0048% $ 89.4k |
3.3yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de RXST se considera experimentada (3.3 años de antigüedad promedio).